Ambrosia Biosciences

World-class chemistry, best in-class therapeutics

press

Ambrosia Biosciences Further Strengthens Board of Directors with Appointment of Jason Haddock

Overview

Ambrosia Biosciences Inc. is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.

Who we are

Meet the team

Together, we are united in our goal to deliver safe, effective, and affordable small molecule drugs that transform lives globally.

Nick Traggis

Founder and Chief Executive Officer

John Mayer, PhD

Founder and Chief Scientific Officer

Faraz Naqvi, MD

Founder and Medical Director

Patrice Lee, PhD

Vice President of Research & Development / Head of Pharmacology

Andrea Flynn, PhD

Chief Business Officer

Ben Carver

General Counsel

Kenny Edwards

Vice President of Finance

Erik Hicken, PhD

Head of Chemistry

Kyle Lefkoff

Founder and Chairman

Nick Traggis

Founder and CEO

David Snitman, PhD

Founder and Director

William Marshall, PhD

Founder and Director

John Orwin

Founder and Director

Jason Haddock

Director

John Mayer, PhD

Scientific Advisory Board Chairman

Richard DiMarchi, PhD

Scientific Advisory Board

Thomas Hughes, PhD

Scientific Advisory Board

Nick Saccomano, PhD

Strategic Advisor

Kieran Chacko, PhD

Strategic Advisor

Our strategic network

Investors

We partner with seasoned biotech investors and industry partners who share our purpose, leveraging their expertise to drive forward our drug discovery programs.

//01.

BVF Partners

Visit BVF Partners

//02.

Boulder Ventures

Visit Boulder Ventures

//03.

Merck

Press

Newsroom

Ambrosia Biosciences Further Strengthens Board of Directors with Appointment of Jason Haddock

Ambrosia Biosciences Announces $25MM Series A Financing, Including Strategic Investment by Merck

Ambrosia Biosciences Announces Series A Financing

Copyright © 2024-2025 Ambrosia Biosciences. Privacy Policy | Cookie Policy